

CD3E&CD3D

Catalog # PVGS1846

Product Information

Primary Accession Species	Q95LI5.2 (CD3E)&Q95LI8 (CD3D) Cynomolgus
Sequence	Gln22-Asp117(CD3E)&Phe22-Ala105(CD3D)
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μ g by the LAL method.
Biological Activity	Measured by its binding ability in a functional ELISA. Immobilized CD3E&CD3D hFc Chimera, Cynomolgus at 0.5 μ g/ml (100 μ l/well) on the plate can bind Biotinylated Anti-CD3E&CD3D Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System	HEK293
Theoretical Molecular Weight	36.9 kDa (CD3E) and 35.4 kDa (CD3D)
Formulation Reconstitution	Lyophilized from a 0.22 μ m filtered solution in PBS , (pH 7.4). Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μ g/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	T-cell surface glycoprotein CD3 epsilon&CD3 delta chain, also known as CD3E&CD3D, are single-pass type I membrane proteins. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain.
--------------------------	---

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.